HUTCHMED DRC (NASDAQ: HCM)

HUTCHMED DRC

NASDAQ: HCM (HUTCHMED (China) Limited)

Last update: 26 Jun, 5:39AM

15.48

-0.36 (-2.27%)

Add to watchlist

Previous Close	15.84
Open	15.64
Volume	69,016
Avg. Volume (3M)	96,243
Market Cap	2,674,696,192

Price / Earnings (TTM)	77.40
Price / Earnings (Forward)	7.86
Price / Sales	4.27
Price / Book	3.47

52 Weeks Range	11.51 (-25%) — 21.50 (38%)
Earnings Date	29 Jul 2025 - 4 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - Specialty & Generic (US)	Bearish	Mixed
	Drug Manufacturers - Specialty & Generic (Global)	Mixed	Mixed
Stock	HUTCHMED (China) Limited	Mixed	Bearish

AIStockmoo Score

0.0

Analyst Consensus	-2.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	3.5
Technical Oscillators	0.5
Average	0.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
HCM	3 B	-	77.40	3.47
UTHR	14 B	-	12.62	1.90
VTRS	11 B	5.15%	-	0.690
NBIX	13 B	-	43.13	4.94
LNTH	6 B	-	23.06	4.80
ALVO	3 B	-	-	-

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Investment Style	Mid Value
% Held by Insiders	0.12%
% Held by Institutions	3.87%

No data within this time range.

Date	Type	Details
03 Jul 2025	Announcement	HUTCHMED to Announce 2025 Half-Year Financial Results
30 Jun 2025	Announcement	HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
04 Jun 2025	Announcement	Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
04 Jun 2025	Announcement	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
01 Jun 2025	Announcement	HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
22 May 2025	Announcement	HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
23 Apr 2025	Announcement	HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
21 Apr 2025	Announcement	HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	5.99%
Operating Margin (TTM)	-4.99%
Diluted EPS (TTM)	0.200
Quarterly Revenue Growth (YOY)	6.40%
Quarterly Earnings Growth (YOY)	-84.70%

Total Debt/Equity (MRQ)	11.64%
Current Ratio (MRQ)	2.83
Operating Cash Flow (TTM)	-46.98 M
Levered Free Cash Flow (TTM)	-50.75 M

Return on Assets (TTM)	-2.14%
Return on Equity (TTM)	5.04%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)